Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT05387967

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05387967
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05387967. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2021-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
Condition
Heart Failure, Systolic
Intervention (Drug)
Sacubitril/valsartan
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)

Record details

Record id
cardio:ct-nct05387967
Content hash
989f9a0665f5a3924d14a13d21b55978dba5f86ff4264b8a19bd8882bc57a0da